Built on proprietary data, we discover and develop bacteriocins to prevent disease and improve health.
Antibiotics work broadly, and that's the problem. Organicin replaces indiscriminate action with thoughtful intervention, using CinThesis and its six axes of analysis to map, compare, and score natural bacteriocins, finding the right peptide for the right pathogen.
For 3.5 billion years, bacteria have been running the longest R&D program on Earth. They have refined bacteriocins, ultra-specific antimicrobial peptides used to compete for space and resources. This is evolution's weapon of choice.
Antibiotics act broadly and disrupt the entire microbiome. Bacteriocins work with precision. They eliminate defined targets while sparing or enhancing the surrounding microbial community that supports health and resilience.
Organicin harnesses billions of years of evolutionary R&D to find the perfect natural candidate for your specific challenge. Instead of reinventing the wheel, we identify the natural candidate that fits your target.
CinThesis
CinThesis: A bacteriocin discovery platform.
CinThesis analyzes more than 500 structural, functional, and evolutionary features for every candidate bacteriocin. This provides a deep view of each molecule's potential activity, selectivity, and stability before any wet-lab work begins, enabling faster exploration of the natural bacteriocin universe.
Every candidate is evaluated through six independent analysis streams: physicochemical properties, structural architecture, evolutionary context, functional domains, three-dimensional structure prediction, and biological language encoding. These streams reveal which molecules nature has already optimized for potency, specificity, and manufacturability.
Proteosemantic Intelligence translates CinThesis outputs into clear biological insight. It explains how a molecule likely works, which structural or evolutionary patterns matter, and what experiments should come next. This gives teams a meaningful understanding of each candidate rather than a list of disconnected metrics.
Vibrio parahaemolyticus
Targeting Acute Hepatopancreatic Necrosis Disease (AHPND) and Early Mortality Syndrome (EMS).
Our candidate also addresses Translucent Post-Larva Disease (TPD) and White Feces Syndrome, as Vibrio parahaemolyticus is a primary causative agent for these conditions. Demonstrated strong controlled-trial outcomes and is advancing through field validation.
Clostridium perfringens
A targeted bacteriocin candidate for preventing necrotic enteritis in broiler chickens by inhibiting Clostridium perfringens while preserving microbiome health.
Target Confidential
Developing bacteriocins for pet nutrition.
Target Confidential
Developing bacteriocins for animal health.
We work with partners across animal nutrition, animal health, and adjacent microbiome applications to create bacteriocin-based solutions.
Partnerships
For collaboration, licensing, or co-development opportunities with CinThesis or our bacteriocin programs, reach out to our team through the forms below.
